The use of CCL5-neutralizing antibody or CCR3/CCR5 inhibitors efficiently neutralized CAF-derived CCL5 or blocked CCR3/CCR5 activation, thereby abolishing the promotion of CCL5 on HCC metastasis. This evidence concerns the gene CCR5 and hepatocellular carcinoma.